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Circadian Variation of Ventricular Arrhythmias is
of Importance for Effective Drug Therapy
Thomas S. Faber. Manfred Zehender. Martin Baumgarten. Andreas Jeron,
Armin Furtwangler. Hanjorg Just. Universitiitsklinik Fre/burg, Innere Medizin 11/.
Germany
With regard to the restrictive and safe use of class I-antiarrhythmics (AA)
clinical criteria predicting drug efficacy and safety have become important.
In 140 pts (102 men. 63 ± 7 years) with frequent and symptomatic. but
not life-threatening arrhythmias (VA; >30fh) occurrence. reproducibility and
therapeutic consequences of a circadian distribution (CD) of single/repetitive
VA was studied. Pts underwent 3 24 h-Holter recordings at baseline. after 2
weeks of placebo and after 6 weeks of dose-titrated antiarrhythmic therapy.
67/140 pts (48%) had reproducible day-night CD (daytime VA increase: 50/67
pts. 75%). In Cox's regression analysis CD was characteristic of a lower VA
rate (p < 0.05), but more frequent tachycardia episodes (risk: 3.8 times. p <
0.05) and a lower ejection fraction. AA response was better in pts with CD
(3.3 times. p < 005). Day-/night CD pattern was also predictive for a superior
response of class IA or IC agents (Fig.).
three times daily. In each case tilt test was negative after 6 weeks treatment
and they all remained free of symptom during a follow up of 6 ± 1 months.
Only 3 of the 8 patients in group B with positive tilt testing at the 6th week
were controlled with metoprolol. The circulating catecholamines levels at
baseline and during tilt testing were not significantly different between pa-
tients successfully treated by metoprolol or disopyramide. The changes of
the neurohormones were not different during disopyramide and metoprolol
treatments. We conclude that 100 mg daily metoprolol is significantly less
efficient than disopyramide 300 mg daily in the long term treatment of recur-
rent neurocardiogenic syncope.
In conclusion. CD of VA is common in half of the pts with symptomatic VA.
When class I agents are used. CD provides clinical evidence for selection of
the most effective AA and dose and may help to improve overall antiarrhyth-
mic benefit.
'p < 0.05 vs C, "p < 0.01 vs C,D,P
Either after P or D + P heart rate resulted lower than control not only at
Aim olthe study was to evaluate the effect of digoxin (D) in combination with
propafenone (P) on the ventricular rate during stable atrial fibrillation (AF).
We evaluated 15 patients (pts.) (age 57 ± 9 years. NYHA :::: 2) with stable AF
during effort by cycloergometer in a randomized study with four phases: 1)
no treatment, for control (C). 2) in steady state treatment with oral digoxin (D)
at at 0 125--0.375 mg/die according to serum digoxin levels (0.8-1 .8 ng/ml).
3) three hours after oral loading with propafenone (P) at 600 mg. and 4) three
hours after oral loading with propafenone while assuming oral digoxin (D +
Pl. The sequence of C. D, P and D + P phases was randomised and the
exercise tests were performed every 7-10 days at the same. Resu/ts:
Effects of Propafenone Plus Digoxin on
Ventricular Rate During Atrial Fibrillation: A
Randomized Study
Alessandro Capucci, Giuseppe Boriani, Gianluca Botto, Silvia Pernpruner,
Camillo Falcone, Andrea Rimondini. Salvatore De Paola. Leonardo Spedicato,
Mauro Bifti, Davide Agnelli, Walter Bonini. Bruno Magnani. Ins! of Cardiology, Univ.
of Bologna and the Atrial FIbrillation Study Group. Italy
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Metoprolol Versus Disopyramide in the
Management of Recurrent Neurocardiogenic
Syncope
Emile G. Daoud, Mark J. Niebauer, K. Ching Man. S. Adam Strickberger,
William Kou, Fred Morady. Veteran Affairs Medical Center and University of Michigan
Hospital. Ann Arbor, MI
In retrospective studies. quinidine-induced proarrhythmia and excessive
lengthening of the OT inteNal have been described to occur in 5-10% of
patients (pts). There are, however. no prospective studies. Therefore, the pur-
pose of this study was to prospectively assess the acute effects of quinidine
on the OT interval and on the incidence of proarrhythmic events in hospi-
talized pts. using daily 12-lead ECG's and continuous telemetric monitoring.
Clinical data included gender. age. body surface area, left ventricular ejec-
tion fraction (LVEF), etiology of heart disease, congestive heart failure class,
O-wave infarction pattern, indication for quinidine. quinidine and potassium
serum levels. and use of a diuretic. digoxin or an antiarrhythmic agent. Pts
were followed until time of discharge. Ouinidine was initiated in 35 pts (18
M; 17 F) for supraventricular (n ~ 221 or ventricular (n = 13) arrhythmias 19
pts had an ischemic, 6 had a non ischemic, and 3 had a valvular cardiomyopa-
thy; 5 had hypertensive and 2 had no heart disease. The mean age was 63
± 13 years. the mean LVEF was 0.38 ± 0.15 and the mean functional class
was 2.0 ± 1.1. The mean quinidine level was 2.7 ± 1.2 iL9/ml.
The OT interval increased from 388 ± 61 to 499 ± 70 msec (p < 0.01) and
the OTc increased from 445 ± 61 to 543 ± 60 rnsec (p < 0.005). 11 pts (31 %)
developed a OTc > 550 msec. Torsade de pointes In = 3) or other ventricular
proarrhythmic events (n = 3) occurred in 6 pts (17%). The pts experiencing
torsade de pointes were female pts with a mean LVEF of 0.24 and a OTc of
610 to 650 msec. Female gender (p = 005). younger age (p ~ 0.04). lower
LVEF Ip = 0.01). and an increased baseline OTc inteNai (p < 0.005) were
statistically associated with proarrhythmia. Proarrhythmic events occurred
on day 23 ± 1 of quinidine therapy (range: 1-41.
In conclusion. in this prospective study of hospitalized pts. quinidine re-
sulted in lengthening of the OTc inteNal beyond 550 rnsec in 31 % of the
pts and in a 17% incidence of clinically significant ventricular proarrhythmia.
Proarrhythmia was statistically associated with female gender. decreased
LVEF and increased baseline OTc inteNal. The results of this prospective
study indicate that the incidence of quinidine-induced proarrhythmia and ex-
cessive OT prolongation may be higher than the 5-1 0% incidence previously
reported in retrospective studies.
phases of sustained (2:1 min) atrial flutter or atrial tachycardia; in these ar-
rhythmia after PFN AV conduction ratio was 2; 1 in 2 cases (ventricular rate
115-140/minl and 2:3: 1 in the others (ventricular rate 60--95/min) while af-
ter PLA AV conduction was 1: 1 in 1 case (ventricular rate 240/min), 2: 1 in 3
cases (ventricular rate 120-150/min) and 2:3: 1 in the others (ventricular rate
60-100/min). Pauses> 2 s occurred in 1 case after PFN and in 3 after PLA.
Moreover after PFN slight hypotension occurred in 5 patients, together with
bradycardia in 3 cases, and ORS enlargement to more than 0.12 s was ob-
seNed in 3 cases. In conclusion oral loading with PFN is a very effective reg-
imen for converting recent-onset AF to SR. Because of its favourable safety
profile, its employement, under clinical control. in selected patients without
left ventricular dysfunction or heart failure. is advisable. Finally, in patients
with recent-onset AF phases of atrial flutter or atrial tachycardia may occur
not only after PFN but even after PLA.
Prospective Assessment of Quinidine-induced QT
Prolongation and Proarrhythmia in Hospitalized
Patients
We evaluate the efficiency of 50 mg oral metoprolol twice daily as compared
to 100 rng oral Disopyramide three-time daily for the treatment of recur-
rent neurocardiogenic syncope. Seventy patients were reffered to our center
since January 1992, for the diagnosis of vasovagal syncope. In 19 cases the
syncope was finally related to a cardiac or neurologic cause. Fifty one pa-
tients (73%) had bradycardia or asystole during tilt testing (70 degrees for
less than 20 minutes without isoproterenol infusion). These patients were
treated by either 50 mg metoprolol twice daily (group A, n = 251 or 100 mg
disopyramide three-times daily (group B. n = 25). Evaluation consisted on
tilt testing 6 weeks after onset of treatment and clinical evaluation one year
after. In case of positive tilt testing 6 weeks after treatment, the patient re-
ceived the opposite treatment and was evaluated again 6 weeks after. Seven
of group A 128%) had a negative controlled tilt test 6 weeks after treatment
onset versus 17 patients in group B (68%. p = 0002). Only 6 patients (24%)
in group A remained asymptomatic during a follow up of 12 ± 2 months
versus 15 patients in group B (60%, p = 0.001). The 18 patients in group A
having a positive tilt test at the 6th week, received 100 mg oral disopyramide
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